Cargando…
COVID-19: Pharmacology and kinetics of viral clearance
Coronavirus Disease 2019 (COVID-19) is a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical spectrum of COVID-19 is broad and varies from mild to severe forms complicated by acute respiratory distress and death. This heterogeneity might reflect...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834389/ https://www.ncbi.nlm.nih.gov/pubmed/32758635 http://dx.doi.org/10.1016/j.phrs.2020.105114 |
_version_ | 1783642270315053056 |
---|---|
author | Farina, Nicola Ramirez, Giuseppe A. De Lorenzo, Rebecca Di Filippo, Luigi Conte, Caterina Ciceri, Fabio Manfredi, Angelo A. Rovere-Querini, Patrizia |
author_facet | Farina, Nicola Ramirez, Giuseppe A. De Lorenzo, Rebecca Di Filippo, Luigi Conte, Caterina Ciceri, Fabio Manfredi, Angelo A. Rovere-Querini, Patrizia |
author_sort | Farina, Nicola |
collection | PubMed |
description | Coronavirus Disease 2019 (COVID-19) is a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical spectrum of COVID-19 is broad and varies from mild to severe forms complicated by acute respiratory distress and death. This heterogeneity might reflect the ability of the host immune system to interact with SARS-CoV2 or the characteristics of the virus itself in terms of loads or persistence. Information on this issue might derive from interventional studies. However, results from high-quality trials are scarce. Here we evaluate the level of evidence of available published interventional studies, with a focus on randomised controlled trials and the efficacy of therapies on clinical outcomes. Moreover, we present data on a large cohort of well-characterized patients hospitalized at a single University Hospital in Milano (Italy), correlating viral clearance with clinical and biochemical features of patients. |
format | Online Article Text |
id | pubmed-7834389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78343892021-01-26 COVID-19: Pharmacology and kinetics of viral clearance Farina, Nicola Ramirez, Giuseppe A. De Lorenzo, Rebecca Di Filippo, Luigi Conte, Caterina Ciceri, Fabio Manfredi, Angelo A. Rovere-Querini, Patrizia Pharmacol Res Review Coronavirus Disease 2019 (COVID-19) is a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical spectrum of COVID-19 is broad and varies from mild to severe forms complicated by acute respiratory distress and death. This heterogeneity might reflect the ability of the host immune system to interact with SARS-CoV2 or the characteristics of the virus itself in terms of loads or persistence. Information on this issue might derive from interventional studies. However, results from high-quality trials are scarce. Here we evaluate the level of evidence of available published interventional studies, with a focus on randomised controlled trials and the efficacy of therapies on clinical outcomes. Moreover, we present data on a large cohort of well-characterized patients hospitalized at a single University Hospital in Milano (Italy), correlating viral clearance with clinical and biochemical features of patients. Elsevier Ltd. 2020-11 2020-08-03 /pmc/articles/PMC7834389/ /pubmed/32758635 http://dx.doi.org/10.1016/j.phrs.2020.105114 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Farina, Nicola Ramirez, Giuseppe A. De Lorenzo, Rebecca Di Filippo, Luigi Conte, Caterina Ciceri, Fabio Manfredi, Angelo A. Rovere-Querini, Patrizia COVID-19: Pharmacology and kinetics of viral clearance |
title | COVID-19: Pharmacology and kinetics of viral clearance |
title_full | COVID-19: Pharmacology and kinetics of viral clearance |
title_fullStr | COVID-19: Pharmacology and kinetics of viral clearance |
title_full_unstemmed | COVID-19: Pharmacology and kinetics of viral clearance |
title_short | COVID-19: Pharmacology and kinetics of viral clearance |
title_sort | covid-19: pharmacology and kinetics of viral clearance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834389/ https://www.ncbi.nlm.nih.gov/pubmed/32758635 http://dx.doi.org/10.1016/j.phrs.2020.105114 |
work_keys_str_mv | AT farinanicola covid19pharmacologyandkineticsofviralclearance AT ramirezgiuseppea covid19pharmacologyandkineticsofviralclearance AT delorenzorebecca covid19pharmacologyandkineticsofviralclearance AT difilippoluigi covid19pharmacologyandkineticsofviralclearance AT contecaterina covid19pharmacologyandkineticsofviralclearance AT cicerifabio covid19pharmacologyandkineticsofviralclearance AT manfrediangeloa covid19pharmacologyandkineticsofviralclearance AT roverequerinipatrizia covid19pharmacologyandkineticsofviralclearance |